By developing medicines to control gene expression, we aim to make a profound difference in the lives of patients and their families.
At the heart of all our efforts at Syros is our dedication to advancing medicines that provide a profound benefit for patients with difficult-to-treat diseases.
We have a singular focus on developing and delivering new standards of care for the frontline treatment of hematologic malignancies. We currently have programs in clinical development for genomically defined patients with MDS and AML.
Interested in participating in a clinical trial?